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Introduction
Age-related macular degeneration (AMD) is the leading cause of vision loss among the elderly in developed countries. The advanced form of the disease is characterized by abnormal blood vessel growth and formation of a choroidal neovascular (CNV) membrane under the macula. Population-based epidemiological studies by Vanderbeek in 2011 compared the incidence of exudative AMD among different races in 113,234 individuals. For baseline reference, African-Americans have the most melanin, Asians have an intermediate level, and light-skinned individuals of mixed European descent have the lowest. Relative to what is found in light-skinned individuals of mixed European descent, exudative AMD is 55% less frequent in African-Americans and 46% less frequent in Asian-Americans. These findings support the hypothesis that lower pigmentation is a risk factor for neovascular AMD (1) (2) (3) . Studies examining the correlation between race, ethnicity, and incidence of uveal melanoma indicate an influence of iris color on the disease. The frequency of uveal melanoma is highest in light-skinned individuals of mixed European descent, followed by Hispanics, Asians, and African-Americans, with an 18:1 ratio of incidence between light-skinned individuals of mixed European descent and African-Americans (4) (5) (6) . Similar to the trend of occurrence seen with wet AMD, cutaneous melanoma and infantile hemangioma are much more prevalent in light-skinned individuals of mixed European descent than African-Americans. These facts suggest that low levels of melanin correlate with the development of angiogenic ocular and skin diseases. Since intracellular pigment levels of retinal pigment epithelium (RPE) cells do not differ greatly among races, our studies focused on melanocytes, the main source of ocular pigment.
Functionally, melanin surrounds the nucleus of a cell to protect DNA from the harmful effects of UV radiation (7) . In the eye, pigment is limited to the uveal tract, consisting of the iris, ciliary body, and choroid, where it protects against UV-induced damage (8) . Melanogenesis is the cellular process of pigment production that occurs in melanosomes. These specialized organelles are surrounded by a lipid membrane within the melanocyte, one of the few cell types that can synthesize melanin. In the skin, melanocytes can distribute melanin-containing melanosomes to surrounding cells such as keratinocytes. The process of melanogenesis is stimulated by several effectors including UV irradiation, melanocyte-stimulating hormone (α-MSH), and FGF2 (7, (9) (10) (11) (12) . The melanin biosynthesis pathway is initiated with tyrosinase-mediated conversion of the amino acid tyrosine to dopaquinone. The pathway is also dependent on 2 related enzymes, tyrosinase-related protein-1 (TRP-1), which results in the production of black rather than brown melanin, and TRP-2, which acts as a dopachrome tautomerase, isomerizing the melanogenic intermediate L-dopachrome to 5,6-dihydroxyindole-2-carboxylic acid (DHICA) in the biosynthesis of melanin. L-dopachrome will also spontaneously decarboxylate to form 5,6-dihydroxyindole (DHI), a second melanin precursor (13) . As a key enzyme in pigment synthesis, mutations in the tyrosinase gene led to catalytically inactive enzyme or a complete lack of the protein. This can result in the absence of melanin, producing a condition known as albinism (13) (14) (15) (16) (17) .
Local regulation of angiogenesis is dependent on the balance between endogenous inhibitors and stimulators. This balance is determined by genetic factors inherited as quantitative traits in a variety of in vivo angiogenesis models (18) . Based on these findings and the human epidemiological data linking lighter skin color with angiogenic diseases, we investigated whether melano-cytes have a role in regulating angiogenesis in pigmented tissues. To test this hypothesis, we examined angiogenesis in numerous models using pigmented (C57BL) or albino C57BL/6J (C57) mice.
Results

Effects of pigmentation on angiogenesis.
To determine the effect of pigmentation on angiogenesis, we performed the corneal neovascularization assay in 2 strains of mice that are genetically identical except for expression of the tyrosinase gene. We implanted FGF2 pellets (80 ng) into corneal micropockets of WT C57 (C57BL expressing normal tyrosinase) and mutant B6(Cg)-Tyr c-2J /J mice (C57-albinos, which have a G→T at nucleotide 291 in the tyrosinase gene, nullifying expression) and examined blood vessel growth in the cornea (which does not contain melanocytes) and the underlying iris (which contains melanocytes) 5 days after pellet implantation ( Figure 1, A and B ). Upon gross examination, we observed that neovascularization in the cornea appeared similar in both the C57-albino and C57BL mice ( Figure 1A ). However, the C57-albino mice developed iris neovascularization with hyphemas (blood in the anterior chamber) with much higher frequency than the C57BL mice ( Figure 1A ). In order to compare neovascularization of the iris, where vessel growth has been stimulated by the FGF2 in the corneal pellet, we injected both strains intravenously with FITC-conjugated BS-1 lectin to label perfused blood vessels. We observed aggressive neovascularization in the C57-albino iris ( Figure 1B ) to a 9-fold greater extent than in C57BL mice, as measured by increased fluorescent iris vessel area (VA) 5 days after pellet implantation ( Figure 1C ). Additionally, we performed analysis of vWF, a constitutive endothelial cell protein, as a marker of endothelial cells in the iris. Western blot analysis revealed more vWF in protein lysates from nonpigmented (C57-albino) irises after FGF2 stimulation, validating the observation that FGF2 pellets in nonpigmented mice induced more new blood vessel growth (Supplemental Fig- To determine whether these findings were ocular specific, we investigated angiogenesis in pigmented versus albino murine skin. We began by measuring baseline cutaneous vessel density, as visualized by CD31 immunofluorescent staining, and observed no significant difference ( Figure 1D ). We then sought to determine whether wound angiogenesis was differentially affected by skin pigmentation. To that end, we created a 1-mm full-thickness punch biopsy wound in the ears of each strain and measured subsequent vessel formation into the wound edge. Since these new vessels provide a conduit for nutrients and other mediators, their ingrowth is an essential feature of wound repair. Five days after wounding, we injected mice intravenously with FITC-conjugated dextran to visualize perfused blood vessels ( Figure 1E ). Consistent with our results in the iris, we observed that mean fluorescent vascular area around the wound was 2.5-fold greater in C57-albino mice than in C57BL mice ( Figure 1F ).
To study the molecular mechanism responsible for the observed differences in angiogenesis between C57-albino and C57BL mice, we utilized an in vitro coculture system. It has been demonstrated that the ability of capillary endothelial cells to migrate and form tubes is essential for new sprout formation (19) . Thus, we examined the migratory capacity of human dermal microvascular endothelial cells (HMVEC) in response to conditioned medium (CM) from immortalized, amelanotic melanocytes isolated from Balb/c albino mice. Balb/c melanocytes express enzymatically-inactive tyrosinase due to a homozygous point mutation (TGT→TCT) in the tyrosinase gene resulting in a lack of melanin (20) . So that they would serve as a control cell line, pigmentation was restored in these cells by correcting the point mutation using an RNA-DNA oligonucleotide (gift from Alexeev Y. Vitali; Thomas Jefferson University, Philadelphia, Pennsylvania, USA) (Supplemental Figure 2 ).
Analysis of HMVEC migration revealed no significant difference upon exposure to control (unconditioned) medium and CM from pigmented melanocytes (average of 32 cells migrated per 100 μm 2 field for both) ( Figure 1G ). However, migration of HMVECs toward CM from nonpigmented melanocytes was 50% higher than control (an average 50 cells/field versus 32) ( Figure 1G ). These data suggest that nonpigmented melanocytes secrete a stimulator of HMVEC migration, rather than pigmented melanocytes secreting an inhibitory factor. To further elucidate this finding, pigmented melanocytes were grown in medium lacking tyrosine, thereby arresting new melanin synthesis. CM from these cells was found to stimulate HMVEC migration 50% over control, a promigratory effect mimicking that of nonpigmented melanocytes ( Figure 1H ). Similar results were observed with CM from cultured, primary human melanocytes isolated from the epidermis of light-skinned individuals of mixed European descent or African-Americans. Specifically, CM from melanocytes from light-skinned individuals of mixed European descent increased migration of HMVECs 1.5-fold compared with CM from the more highly pigmented African-American melanocytes ( Figure 1I ). Collectively, these findings indicate that melanocytes can secrete a stimulator of EC migration. We then sought to determine whether the CM from pigmented and nonpigmented melanocytes also differentially influenced endothelial cell survival and/or proliferation. As such, we performed cell proliferation assays with HMVECs in the presence and absence of CM from pigmented and nonpigmented human and murine melanocytes. We exposed HMVECs to respective CMs for 2 days, after which cell viability was evaluated using WST-1 reagent. We observed that CM from nonpigmented murine melanocytes promoted HMVEC viability and proliferation more than that of pigmented murine melanocytes ( Figure 1J ). Additionally, human melanocytes from light-skinned individuals of mixed European descent stimulated HMVEC proliferation to a greater extent than African-American melanocytes ( Figure 1K ). Taken together, our data suggest that low-pigmented melanocytes secrete a stimulator of endothelial cells.
Nonpigmented melanocytes secrete fibromodulin. To investigate the molecular mechanism responsible for stimulation of angiogenesis by amelanotic melanocytes, we performed microarray-based gene expression analysis of pigmented and nonpigmented melanocytes (see Methods). For this analysis, we employed a candidate gene approach in which candidates were selected using the following criteria: first, mRNA showing greater than 10-fold increased expression by nonpigmented over pigmented melanocytes was selected. Of these, candidates were selected if their encoded proteins were (a) known to be secreted, (b) had high homology between mouse and human, and (c) were previously implicated in either angiogenesis or AMD. An intriguing candidate which emerged from these criteria was fibromodulin (FMOD). FMOD is a 42-kDa secreted protein belonging to the leucine-rich repeat protein family of proteoglycans that interacts with collagen types I and II (21-23) and is known to contribute to inflammatory path-ways (24) . FMOD protein localizes to the cytosol and contains a secretory sequence (25) (26) (27) (28) (29) (30) (31) . While at present there are no reports directly linking FMOD to AMD, it is known that a major point of susceptibility for the development of AMD is complement factor H (CFH), an immune regulator that inhibits complement activa-tion (32) . Poor binding of CFH to FMOD frees CFH to bind C1q, leading to complement activation and resulting pathological processes. Thus, we investigated whether FMOD may be one of the proteins responsible for the pigment-mediated difference in angiogenic diseases of tissue-containing melanocytes. Figure 2C ). Given this, we sought to examine variances in gene expression of FMOD mRNA between pigmented and nonpigmented cells using real-time RT-PCR analysis and immunofluorescent staining. We found that nonpigmented mouse melanocytes express dramatically more (40-fold) FMOD mRNA than pigmented melanocytes ( Figure 2A ). Immunohistochemical staining further confirmed this observation ( Figure 2B , red color). Consistently, Western blot analysis revealed that CM from human melanocytes isolat-ed from light-skinned individuals of mixed European descent contained higher levels of FMOD protein than melanocytes of African-Americans ( Figure 2C ).
Initial cell culture experiments verified that nonpigmented melanocytes have high expression levels of FMOD, whereas pigmented melanocytes express low levels (shown in
To investigate the localization of FMOD in ocular tissue, we performed immunofluorescent staining for FMOD on cryosections from C57-albino and C57BL mouse retinas. Strong FMOD staining was seen in the nonpigmented choroids of C57-albino mice ( Figure 2D ), but not in the heavily pigmented choroids of C57BL mice ( Figure 2E ). To confirm that the presence of melanin in the tissue of WT mice did not simply mask the fluorescent staining, FMOD levels were also assessed by Western blot analysis in iso- lated choroids ( Figure 2F) , irises, and ciliary bodies ( Figure 2G ). As predicted, C57-albinos consistently expressed higher levels of FMOD throughout the ocular tissue than WT C57BL mice.
Our next aim was to examine whether tyrosinase itself, or a soluble melanin intermediate, was responsible for the regulation of FMOD expression in pigmented tissue. To elucidate this, we examined normal, pigmented melanocytes cultured in medium lacking tyrosine. In the absence of tyrosine, cells do not actively produce new intermediate melanin products nor new melanin (brown black polymer). Resultant FMOD expression was then analyzed by Western blot ( Figure 2H) ; similar results were shown in CM from pigmented cells (Supplemental Figure 3 ). Our findings revealed that, despite the presence of preexisting melanin inside the cells, removal of tyrosine from the medium resulted in increased FMOD expression at a level consistent with that seen in nonpigmented cells. This indicates that it is not the final insoluble end product of melanin polymer, but rather an earlier intermediate factor produced in the process of functional melanogenesis, that has direct effects on FMOD production. As a further step, we screened the known soluble melanin intermediates for effects on FMOD expression. Nonpigmented cells were cultured in medium lacking tyrosine to which we added individual soluble melanin intermediary products such as DHI. DHI is essential for melanin formation via tyrosinase by catalyzed oxidation of tyrosine (33) . Albino melanocytes supplemented with DHI produced a reduced level of FMOD compared with nonsupplemented cells (Figure 2I) , showing that intermediates of the melanogenesis process influence cellular expression of FMOD.
FMOD stimulates endothelial cell functions in vitro. To show that a substantial component of the stimulatory effects of albino CM on HMVEC migration and proliferation was due to FMOD expres- sion, we next neutralized FMOD. Inhibiting FMOD in the CM via neutralizing antibody resulted in reduced HMVEC migration as compared with control IgG-treated CM ( Figure 3A ). Additionally, siRNA was used to knock down FMOD expression in nonpigmented murine melanocytes and silencing was confirmed by Western blot (Figure 3B ). In a coculture experiment, we observed that siRNAmediated silencing of FMOD in the melanocytes resulted in 35% reduction of HMVEC migration ( Figure 3C ). We found that CM from pigmented melanocytes was unable to stimulate migration and proliferation of endothelial cells. To determine whether this inability was due to the low expression of FMOD, exogenous FMOD was added to the CM. Supplementation of FMOD into CM from pigmented melanocytes increased HMVEC migration by 2-fold in comparison with control ( Figure 3D ). Indeed, recombinant FMOD protein alone stimulated HMVEC migration and proliferation in a dose-dependent fashion (Figure 3 , E and F, respectively).
To investigate FMOD's ability to promote angiogenesis, a multistage process that involves endothelial cell growth, motility, and extracellular matrix degradation, we performed a 3D in vitro sprouting angiogenesis assay (34, 35) . Examination of HMVEC sprouting after 48 hours revealed that the control fibrin gels failed to promote endothelial cell sprouting ( Figure 3G ). In contrast, fibrin gels containing FMOD stimulated HMVECs to form capillary sprouts, which invaded the gels and produced stable cord- Figure 3G ). This effect resembled the angiogenic response seen with a combination of FGF2 and VEGF-A in the positive control ( Figure 3G ). Detailed quantitative analysis by ANOVA revealed that 1.5 nM FMOD (75 sprouts) and positive control FGF2/VEGF-A combination (68 sprouts) produced similar numbers of capillary sprouts per bead ( Figure 3H ). However, FMOD stimulated the formation of significantly (57%) longer capillary structures (>150 μm) ( Figure 3I ). This FMOD-induced augmentation of capillary sprouting is consistent with its ability to form an extensive capillary network on 2D Matrigel (Supplemental Figure  4) . Additionally, we conducted spheroid assays to provide enhanced imaging of the vasculature. This 3D in vitro assay simulates the proteolytic activity, migration and proliferation of the angiogenic process. HMVECS incubated for 24 hours in collagen type I with 4.5 nM recombinant FMOD had elevated outgrowth of sprouts when compared with those incubated in collagen alone (Supplemental Figure 5 ). Taken together, these in vitro assays demonstrate that FMOD is a potent stimulator capable of influencing pivotal steps in the angiogenic process, including endothelial cell proliferation, migration, sprouting, and capillary network formation.
FMOD stimulates angiogenesis in vivo. We next investigated the effect of FMOD on capillary formation in vivo. We utilized a model combining HMVECs with human bone marrow-derived mesenchymal stem cells (hBM-MSC), cells which support and stimulate angiogenesis (36) . The cells were suspended in Matrigel and injected subcutaneously into the flanks of nude mice. Plugs were harvested after 7 days. To visualize the pattern of vessel formation and confirm their functional integration with the host vasculature, human-specific rhodamine-labeled lectin was injected intravenously and allowed to circulate for 15 minutes prior to harvesting the Matrigel plugs. The vascular plexus was visualized using laser confocal microscopy. Figure 4A shows that FMOD formed a robust functional capillary plexus with significantly more capillaries branching off larger vessels when compared with HMVEC+hBM-MSC alone.
To demonstrate whether neutralization of FMOD in vivo could correspondingly diminish the angiogenic effect of albino melanocytes, we performed a modified Matrigel assay. Nonpigmented melanocytes were mixed with Matrigel in the presence of anti-FMOD antibody or control IgG and injected subcutaneously. After 6 days, Matrigel plugs were removed and invading mouse CD31-positive endothelial cells were quantified by FACS as previously described (ref. 37 and Figure 4B ). Strikingly, we found that FMOD neutralization reduced the number of CD31-positive cells by 2.25-fold ( Figure 4C) , reinforcing the conclusion that FMOD is an angiogenic factor in amelanotic tissue. We next utilized the corneal micropocket angiogenesis assay to further highlight this role. Pellets containing either FMOD (1.7 pmol/pellet), GST (1.7 pmol/ pellet, negative control), or VEGF-A (5.2 pmol/pellet, positive control) were implanted into the corneas of C57BL mice. Corneas were analyzed 5 days after implantation. FMOD pellets stimulated corneal neovascularization with a VA similar to that seen with 3 times higher amounts of VEGF-A ( Figure 4D ). Evaluation of vessel length showed that FMOD promoted formation of extensive vessel structures ( Figure 4E ), thus mirroring in vitro phenomena ( Figure 3I ). To investigate whether FMOD's activity is unique in its class, we performed negative control studies with lumican, an extracellular matrix protein which is also a member of the small leucine-rich proteoglycans (SLRP). Lumican has high homology to FMOD and binds as well to fibrillar collagens. Although it is known that lumican regulates collagen fibrillogenesis (28) , our experiments showed it to have no effect on angiogenesis (Supplemental Figure 6 ). To determine whether FMOD enhances CNV formation, 4 subretinal laser burns were placed per eye in C57BL mice. On the day of laser induction, intravitreal injection of 35 ng/0.5 μl/eye rh-FMOD or GST (sham injection control) was performed. On day 14, the size of CNV lesions in all groups was measured. The FMOD-treated group was found to have increased CNV, 37.4% compared with the control group ( Figure 5, A and B) .
Continuing our in vivo studies, we then evaluated the proangiogenic effects of FMOD in wound repair, utilizing a cutaneous ear wounding model in C57BL mice. Ear wounds were treated topically with recombinant FMOD (2 μM) or control (GST) daily for 5 days. Neovascularization was evaluated on day 5 by injecting mice with FITC-conjugated dextran to highlight functional blood vessels ( Figure 4F ). Quantification of the fluorescent vessels surrounding the wound demonstrated that treatment with recombinant FMOD yielded a doubling of the mean fluorescent signal when compared with control. These data show that exogenous FMOD increases microvessel density in the wound-healing microenvironment ( Figure 4G ).
We next sought to investigate the potential role of FMOD in developmental angiogenesis. Mice were injected intravitreally with 0.5 μl of 1.19 μM recombinant FMOD or control GST on postnatal day 4. Analysis on day 7 revealed that in control mice, the retinal capillary plexus had expanded from the optic disc in a normal fashion ( Figure 4H ). However, mice treated with FMOD ( Figure 4H ) exhibited a 73% increase in microvessel density ( Figure 4I ) with a corresponding 27% decrease of avascular area in their retinas ( Figure 4J ).
FMOD-deficient mouse strains are currently only available as pigmented mice on the C57BL background. However, since the level of FMOD is already very low in pigmented melanocytes, lowering or blocking FMOD in these animals will not be useful in evaluating the role of melanocyte-secreted FMOD in angiogenic diseases. We believe this is the reason that previous studies with pigmented Fmod-KO mice have failed to expose dramatic differences, due to the inherently low levels of FMOD in black mice. We therefore bred Fmod -/mice (a gift from A. Oldberg, Lund University, Lund, Sweden) onto an albino background (Tyr -/-) to bet-ter examine the role of FMOD in angiogenesis in the absence of pigmentation. We first performed Matrigel angiogenesis assays in the skin of Fmod +/+ (WT) or Fmod -/-(KO) mice in both black (C57) and white (Tyr -/-) backgrounds. We found a dramatic reduction (71.5%) in the number of CD31-positive endothelial cells infiltrating the Matrigel in FMOD-deficient albino mice ( Figure 5C ) compared with control albino mice. Additionally, a similar reduction was found in the number of CD31-positive endothelial cells infiltrating into the Matrigel in black mice (C57BL) compared with white mice (Tyr -/-C57) ( Figure 5C ). As anticipated, we observed minimal differences between experimental angiogenesis elicited in black WT control mice versus black Fmod-KO mice.
In order to compare neovascularization arising in the iris, FGF2 pellets were implanted in the corneas of Fmod +/+ or Fmod -/-(KOs) in both black (C57) and white (Tyr -/-) mice. After 5 days, iris vessels and neovascularization were visualized via intravenous injection with FITC-conjugated BS-1 lectin to label perfused blood vessels. Analysis, performed using Angiotool software (38) , revealed 2.4-fold greater VA in the iris of Fmod +/+ albino mice ( Figure 5D ) when compared with Fmod -/albino mice ( Figure 5E ). Fmod -/mice had a 34% reduction in total vessel length versus WT ( Figure 5F ). We also measured vessel branching and found that it was reduced by 32% in Fmod-KO albino mice ( Figure 5G ).
To further investigate angiogenesis in the KO mice, we performed a pathophysiologic animal model of retinal vein occlusion (RVO) (39) . In this model, iris neovascularization occurs following venous thrombosis, elicited by photocoagulating the vein close to the optic nerve using a laser. 50-μM burns were created with a power setting of 150 mW in white mice. After 14 days, iris vessels and neovascularization were visualized by Alexa Fluor 647 conjugated to lectin GS-II and analyzed by Angiotool software ( Figure 5H ). Measurement of the iris VA of Fmod +/+ albino mice revealed a 40% decrease in iris vessels in Fmod -/albino mice ( Figure 5I ). Further, total numbers of branches were reduced by 38% in Fmod-KO animals ( Figure 5J ).
FMOD stimulates TGFB1 secretion in vitro. To examine how FMOD stimulates endothelial cells, we investigated FMOD's known interaction with TGFB1 (40) . We tested whether FMOD stimulates endothelial migration through the binding of TGFB1. To determine this, we incubated endothelial cells overnight with a TGFB1-neutralizing antibody. After 24 hours, those cells were subject to a standard migration assay as described previously, where cells were stimulated to migrate across an 8-μm Transwell in the presence of positive control, negative control, or FMOD. We observed that TGFB1 antibodies neutralized the promigratory effects of FMOD on HMVEC ( Figure 6A ). To study the molecular mechanism behind this observation, we utilized an in vitro culture and examined secretion levels of the active form of TGFB1 from the extracellular matrix of HMVECs in response to FMOD. After exposing HMVECs to designated concentrations of FMOD, we measured the active form of TGFB1 secreted after 2 hours and found a maximal increase with 0.005 nM of FMOD ( Figure 6B ).
TGFB signaling is mostly mediated via a receptor complex composed of TGFBRII and TGFBRI. TGFB1 signal, through a TGFBRII in association with activin receptor-like kinase 1 (ALK1), activated endothelial cells and resulted in elevated proliferation and migration (41, 42) . This activates the canonical SMAD-dependent pathway via SMAD5 phosphorylation. We found that HMVECs that were incubated with 0.005 nM of FMOD for 30 minutes had increased levels of phosphorylated SMAD5, SMAD1, and TGFRII ( Figure 6 , C-E). This in turn increased levels of SMAD5, SMAD1, and TGFBRII. In order to examine the signaling pathway regulated by SMAD, HMVECs were transduced with a SMAD reporter (lentivirus). After 24 hours, cells were treated with 0.5 nM FMOD overnight. Dual luciferase assay revealed that FMOD activated the SMAD reporter 82-fold over control ( Figure 6F ). We therefore conclude that FMOD's stimulatory effect on endothelial cells functions in part through its ability to bind to TGFB1 and mediate the SMAD-dependent pathway.
Discussion
Angiogenesis, the formation of new blood vessels, is regulated by cytokines and growth factors in a highly orchestrated manner. Based on epidemiological evidence of an association between pigmentation levels and propensity for angiogenic diseases, we hypothesized that melanocytes in the microenvironment contribute to local regulation of neovascularization. Through our experiments, we defined what we believe to be a novel mechanism in which melanocytes secrete a previously unknown angiogenic factor, FMOD ( Figure 5I ). We show that FMOD serves an angiogenic function in tissues containing melanocytes, such as the iris, choroid, and skin. FMOD appears to be a potent stimulator of multiple steps in the angiogenic process, including endothelial cell growth, migration, sprouting, and capillary network formation. Our data reveal that FMOD stimulated blood vessel formation and accelerated neovascularization in 5 independent in vivo models. Additionally, knocking down FMOD in 3 independent in vivo models reduced angiogenesis. Mechanistically, FMOD activates endothelial cells via TGFB1 secretion. This in turn stimulates TGFRII, initiating the SMAD pathway, and ultimately resulting in activation of SMAD transcription factor.
It was previously reported (43) that corneal neovascularization in black mice lacking FMOD is similar to that in black WT mice and that, developmentally, these KOs are viable and fertile (23) . Furthermore, a tumor study conducted in black Fmod-KO mice did not report an influence of FMOD on tumor angiogenesis (44) . In our own studies, we also observed minimal differences between experimental angiogenesis elicited in C57 black Fmod-KO mice versus black WT control mice. However, as our in vitro data has emphasized, the baseline levels of FMOD in pigmented melanocytes are very low compared with those in albino melanocytes. This suggests that Oldberg et al. failed to detect FMOD's effects on the angiogenic process because of the inherently low level of FMOD expression in both groups of their black animals. Therefore, we created albino Fmod-KO mice to evaluate differences in FMOD expression at levels where they can be observationally appreciated and experimentally manipulated. Our experiments reveal a dramatic reduction of angiogenesis in Fmod-KO albino mice compared with WT albinos. Regarding the viability of Fmod-KO mice, we note that there are many strains of mice that have genetic KOs of an angiogenic factor such as thrombospondin, neuropilin, semaphorin, and RhoB, that are both viable and fertile. Thus Fmod-KO mice may not exhibit a gross angiogenic phenotype during development because genetic redundancy often preserves physiological angiogenesis.
In conclusion, we provide genetic and biochemical data that elucidate the epidemiological correlation between pigmentation and susceptibility to angiogenic disease. Our findings suggest FMOD could be a promising therapeutic target for treating pathological angiogenesis, with the potential to ameliorate disease processes affecting pigmented tissues, such as in AMD, melanomas, and hemangiomas.
Wound healing. The dorsal aspect of the ear of C57BL and C57-albino mice was wounded with a circular 1-mm diameter punch. Wound neovascularization was assessed 5 days after wounding by injection of dextran-FITC. To test the effect of FMOD on this angiogenesis model, C57BL mice were wounded with a circular punch of 1 mm and treated daily with reduced growth factor Matrigel containing either recombinant FMOD or recombinant GST. Five days after wounding, mice were injected with dextran-FITC to visualize neovascularization. Pictures were taken with a Nikon Eclipse TE-2000-E fluorescence microscope using a Coolsnap HQ CCD camera. Quantification of newly built vessels was performed using ImageJ.
CNV model. C57 mice were anesthetized with avertin (400 mg/kg). The pupils were dilated with a mixture of 0.5% tropicamide and 0.5% phenylephrine hydrochloride (Santen Pharmaceutical). Lesions were induced by laser (power 150 mW) around the optic nerve through a slit lamp delivery system using a Nidek photocoagulator (GYC2000; Nidek). Four burns were performed per eye around the optic disc. 35 ng/0.5 μl/eye rh-FMOD or GST treatments were injected intravitreally at the day of CNV induction (day 0), and the sizes of CNV lesions were determined after 14 days. Fourteen days after laser induction, mice were euthanized and their eyes were removed and fixed in 4% paraformaldehyde for 60 minutes. The choroids were carefully dissected from the eyecup. Blood vessels were labeled using a 1:200 dilution of isolectin IB4 (Vector Laboratories). Fluorescent images of choroidal flat mounts were captured using a CCD camera (DC500; Leica). The CNV areas, presented in μm 2 , were evaluated using Scion image software.
RVO model. Mice were anesthetized with avertin (400 mg/kg) as described in the CNV model. The pupils were dilated with a mixture of 0.5% tropicamide and 0.5% phenylephrine hydrochloride (Santen Pharmaceutical). Venous points were selected close to the optic nerve through a slit lamp delivery system using a Nidek photocoagulator (GYC2000; Nidek). A power setting of 50 mW for C57 mice and 150 mW for C57-albino mice was applied for a duration of 3 seconds to create a spot size of 50 μm. Five applications were conducted in order to stop blood flow. At 14 days after laser induction, mice were euthanized and their eyes were removed and fixed in 4% paraformaldehyde overnight (39) . The irises were carefully dissected and blood vessels were labeled using a 1:200 dilution of Lectin GSII (Molecular Probes). The fluorescent images of iris flat mounts were captured using a CCD camera (DC500; Leica). The areas of neovascularization (presented in μm 2 ) were evaluated using Scion image software.
Skin immunofluorescence. 20-micron sections of OCT-frozen ears were fixed with acetone and labeled with rat anti-mouse CD31-FITC (BD Biosciences).
Microarray. Microarray data have been deposited in the GEO database (GSE51073).
Statistics. Data are expressed as mean ± SD. Statistical significance was assessed using Student's unpaired 2-tailed t test with Bonferroni correction, as appropriate, or ANOVA. P < 0.05 was considered statistically significant.
Study approval. All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of Boston Children's Hospital.
